(0.24%) 5 119.00 points
(0.03%) 38 736 points
(0.69%) 17 729 points
(0.04%) $83.39
(0.06%) $1.813
(-0.32%) $2 334.60
(-0.17%) $27.32
(0.50%) $927.40
(0.12%) $0.935
(0.19%) $10.92
(0.14%) $0.804
(-0.62%) $92.61
@ $25.17
Issued: 14 Feb 2024 @ 09:30
Return: -18.00%
Previous signal: Feb 13 - 09:31
Previous signal:
Return: -0.59 %
Live Chart Being Loaded With Signals
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally...
Stats | |
---|---|
Today's Volume | 141 900 |
Average Volume | 215 506 |
Market Cap | 614.76M |
EPS | $0 ( 2024-02-28 ) |
Next earnings date | ( $-0.330 ) 2024-05-03 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.67 |
ATR14 | $0.0210 (0.10%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-08 | Hsieh Ming | Buy | 1 000 000 | Forward sale contract (obligation to sell) |
2024-03-08 | Hsieh Ming | Sell | 1 000 000 | Forward sale contract (obligation to sell) |
2024-03-01 | Xie Jian | Sell | 1 075 | Common Stock |
2024-03-01 | Xie Jian | Sell | 404 | Common Stock |
2024-03-01 | Kim Paul | Sell | 1 129 | Common Stock |
INSIDER POWER |
---|
2.45 |
Last 99 transactions |
Buy: 2 068 563 | Sell: 1 956 842 |
Volume Correlation
Fulgent Genetics Inc Correlation
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Fulgent Genetics Inc Correlation - Currency/Commodity
Fulgent Genetics Inc Financials
Annual | 2023 |
Revenue: | $289.21M |
Gross Profit: | $96.61M (33.40 %) |
EPS: | $-5.63 |
Q4 | 2023 |
Revenue: | $70.51M |
Gross Profit: | $23.27M (33.01 %) |
EPS: | $-4.30 |
Q3 | 2023 |
Revenue: | $84.69M |
Gross Profit: | $39.84M (47.05 %) |
EPS: | $-0.440 |
Q2 | 2023 |
Revenue: | $67.85M |
Gross Profit: | $20.57M (30.32 %) |
EPS: | $-0.380 |
Financial Reports:
No articles found.
Fulgent Genetics Inc
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators